Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus

Chinese Journal of New Drugs

Volumn 20, Issue 21, 2011, Pages 2163-2170

  Li, Hong Chao ^a   Xu, Fei ^b   Wang, Fan ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b China Center for Health Economic Research   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Biphasic insulin aspart 30; Cost effective; Cost saving; Insulin glargine; Life expectancy; Neutral protamine hagedorn insulin; QALY

Indexed keywords

INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN;

ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY OF LIFE;

EID: 84859494625     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 2005, 21(5): 5s1-5s5.
2. International Diabetes Federation. Diabetes Atlas(third edition)[R]. 2006.
3. 2008, 27(8): 5-8.
4. YANG W, LU J, WENG J, et al. Prevalence of Diabetes among Men and Women in China[J]. N Engl J Med, 2010, 362: 1090-1101.
5. MBANYA J C. New diabetes figures in China: IDF press statement. (2010-03-24). http://www.idf.org/press-releases/idf-press-statement-china-study.
6. WEI Z X, HE D J, LUO L X. Observation on blood glucose control efficacy of Biphasic insulin analogues and biphasic insulin on type 2 diabetic mellitus[J]. J Nanhua Univ, 2007, 35(6): 904-906.
7. PALMER J L, GIBBS M. Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China[J]. Adv Ther, 2008, 25(8): 752-774.
8. WHITE J, AAGREN M, JING L, et al. Cost-utility analysis of biphasic insulin aspart versus human insulin in type 2 diabetes mellitus patients treated in tier III hospitals in Beijing, China: a long term outcomes model evaluation from IMPROVE observational study(poster) [C]. ISPOR 11th Annual European Congress, 2008.
9. WHITE J, AAGREN M, JING L, et al. Long term health outcomes in newly diagnosed treatment naÏve type 2 diabetes patients initiated with biphasic insulin aspart in China: date from the IMPROVE study(poster)[C]. ISPOR 11TH Annual European Congress, 2008.
10. WHITE J, AAGREN M, JING L, et al. Cost-effectiveness of biphasic insulin aspart in type 2 diabetes in China: results from an observational study(poster)[C]. ISPOR Asia-Pacific Congress, 2008.
11. PALMER A J, ROZE S, VALENTINE W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies[J]. Curr Med Res Opin, 2004, 20(Suppl 1): S27-S40.
12. NORDISK N. Effect of biphasic insulin Aspart 30 combined with metformin on blood glucose control in subjects with type 2 diabetes inadequately controlled with basal insulin. (2010-06-04). http://clinicaltrial.gov/ct2/show/ NCT00669864?term=NCT00669864&rank=1.
13. JIA W P, PANG C, CHEN L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a crosssectional 3-year follow-up study in Shanghai urban communities[J]. Diabetologia, 2007, 50(2): 286-292.
14. YANG G H, MA J M, LIU N, et al. China National Nutrition and Health Survey in 2002[J]. Chin J Epidemiol, 2005, 26(2): 77-83.
15. China Health Care Association.The investigation report over smoking and drinking including Chinese twenty-five provinces in 2007[EB/OL]. [2010-04-27]. http://www.chc.org.cn/news/detail.php?id=51296.
16. World Health Organization. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis [B]. Geneva: World Health Organization, 2003.
17. [2010-02-25]. http://www.stats.gov.cn/tjgb/ ndtjgb/qgndtjgb/t20100225_402622945.htm.